Author

S. G. Remesh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:cryo-EM· 1 Organism:human· 1 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1 Assay:proteomics· 1

Frequent Co-Authors

J. A. Wells· 2 shared K. K. Leung· 2 shared A. A. Kossiakoff· 1 shared A. F. Britol· 1 shared A. Glasgow· 1 shared A. J. Martinko· 1 shared A. M. Smith· 1 shared A. N. Rizo· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

J. A. Wells

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps

S. G. Remesh, G. E. Merz, A. F. Britol, U. S. Chio, A. N. Rizo, T. H. Pospiech, I. Lui, M. T. Laurie, J. Glasgow, C. Q. Le, Y. Zhang, D. Diwanji, E. Hernandez, J. Lopez, K. I. Pawar, , K. A. Verba

The paper develops a computational pipeline combining Rosetta and cryo-EM to analyze ACE2 receptor traps' binding to SARS-CoV-2 variants, showing high affinity and neutralization capabilities against Omicron and Delta.

bioRxiv · Aug 9, 2022Biochemistry

Targeting a proteolytic neo-epitope of CUB-domain containing protein 1 in RAS-driven cancer

S. A. Lim, J. Zhou, A. J. Martinko, Y.-H. Wang, E. V. Filippova, V. Steri, D. Wang, S. G. Remesh, J. Liu, B. Hann, A. A. Kossiakoff, M. J. Evans, K. K. Leung, J. A. Wells

The paper develops antibodies targeting proteolytic neo-epitopes of CDCP1 in RAS-driven cancers, showing improved tumor specificity and safety.

bioRxiv · Jun 14, 2021 · PreprintBiochemistry